Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERDICT ulcerative colitis treat-to-target trial
NL-OMON49621Phase 4Withdrawn
- Sponsor
- Alimentiv
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vedolizumab in autoimmune colitis (3 arms), sponsored by Alimentiv. Primary endpoint: Primary efficacy endpoint. Planned start Aug 2020; status: withdrawn.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON49621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49621.